Results 131 to 140 of about 47,991 (257)

Real‐World Maintenance of Remission in Atopic Dermatitis Patients With Upadacitinib: A Multicenter Retrospective Study in Japan (ROADMAP Study)

The Journal of Dermatology, EarlyView.
ABSTRACT Upadacitinib (UPA) is a selective Janus kinase 1 inhibitor that improves moderate‐to‐severe atopic dermatitis, but real‐world strategies to maintain remission after response remain unclear. We conducted a multicenter retrospective study in Japan of 219 patients aged ≥ 12 years who achieved protocol‐defined remission, defined as Investigator's ...
Yuichiro Tsunemi, Atsuyuki Igarashi, Takeshi Ishido, Hidehisa Saeki   +3 more
wiley   +1 more source

Words matter: reclassifying chronic pruritus of unknown origin as neuroimmune pruritus. [PDF]

JAAD Int
Verma H, Brownstone N.
europepmc   +1 more source

Broadening the View: Substance P and Its Metabolism in Pruritus‐Related Diseases

The Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus is a debilitating symptom accompanying numerous inflammatory skin diseases and remains a major therapeutic challenge. Neurogenic inflammation plays a central role in its pathogenesis, with the tachykinin substance P acting as a key mediator at the interface of the nervous system, immune cells, and cutaneous tissues.
Thomas Walter, Bjoern B. Burckhardt
wiley   +1 more source

From neuroimmune circuits to targeted therapy of chronic pruritus. [PDF]

Pharmacol Rev
Ramcke T, Kaplan DH.
europepmc   +1 more source

Demodex Infestation in Patients With Atopic Dermatitis Treated With Dupilumab: A Case–Control Study

The Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory skin disease in which dupilumab, an interleukin‐4 receptor alpha antagonist, has become a cornerstone therapy for moderate‐to‐severe disease. However, persistent facial and neck erythema and related symptoms have been increasingly reported during dupilumab treatment, and the underlying ...
Pinar Dursun, Ayse Nur Saribas Yildirim, Ayca Yazici   +2 more
wiley   +1 more source

Chronic pruritus of unknown origin: assessment and management in general practice. [PDF]

Br J Gen Pract
Papas C, Muir J, Chan L.
europepmc   +1 more source

Evaluation of chronic pruritus and associated skin findings in patients with diabetes mellitus. [PDF]

Turk J Med Sci, 2023
Avci Merdin F, Aydemir AT, Korkmaz FN, Şah Ünal FT, Gökçay Canpolat A, Öktem A, Demir Ö, Şahin M, Emral R, Erdoğan MF, Güllü S, Tonyukuk Gedik V, Koçyiğit P, Çorapçioğlu D.   +13 more
europepmc   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review. [PDF]

Int J Dermatol
Akiska YM, Gandhi I, Adler R, Fayyad D, Bhagchandani P, Afzal S, Adawi W, Patel S, Kwatra SG.   +8 more
europepmc   +1 more source

Bilateral infantile Frey syndrome mimicking food allergy: A case report

Pediatric Investigation, EarlyView.
Yuki Ohara, Mayumi Fujita, Chisato Inuo
wiley   +1 more source

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre‐Operative PD1 CheckpOint Blockade and Receptor Activator of NF‐κB Ligand (RANKL) Inhibition in Non‐Small Cell Lung Cancer (NSCLC)—A Phase 1B/2 Trial

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Expanding on the growing evidence for neoadjuvant immunotherapy in resectable non‐small cell lung cancer, this study explored neoadjuvant nivolumab ± denosumab. Two of the 10 treated patients achieved a pathological complete response. CD8 T‐cell infiltration correlated with pathological response, warranting ongoing translational research to understand ...
Elizabeth Ahern, Cassie Turner, Rishendran Naidoo, David Godbolt, Amy Ives, Kirsten Popplewell, Zarnie Lwin, Sally Pearson, Kimberley Nelson, Jason Madore, William C Dougall, Brett G. M. Hughes   +11 more
wiley   +1 more source